Search results
AbbVie (NYSE:ABBV) Stock Rating Reaffirmed by Cantor Fitzgerald
ETF DAILY NEWS· 13 hours agoAbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. Cantor ...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Stableford Capital II LLC
ETF DAILY NEWS· 1 day agoStableford Capital II LLC decreased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.2% in the 1st quarter, Holdings Channel reports. The firm owned 5,038 shares of ...
Safeguard Financial LLC Takes $235,000 Position in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 1 day agoSafeguard Financial LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with ...
AbbVie names Roxanne Austin as new lead independent director By Investing.com
Investing.com· 2 days agoAustin will be taking over from Glenn F. Tilton, who will continue his tenure on the board as an...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 1 day agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
Pensionfund Sabic Sells 3,100 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 2 days agoPensionfund Sabic lowered its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 15.7% during the first quarter, according to the company in its most recent Form 13F filing ...
CCM Investment Advisers LLC Trims Stock Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 5 days agoCCM Investment Advisers LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.1% during the 4th quarter, according to the company in its most recent Form ...
AbbVie (NYSE:ABBV) Given New $190.00 Price Target at Piper Sandler
ETF DAILY NEWS· 4 days agoAbbVie (NYSE:ABBV – Get Free Report) had its price objective boosted by research analysts at Piper Sandler from $185.00 to $190.00 in a research note issued on Tuesday, Benzinga ...
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
Zacks via Yahoo Finance· 4 days agoThe latest trading session saw AbbVie (ABBV) ending at $171.36, denoting a +0.99% adjustment from...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 2 days agoOn June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults ...